ORLANDO — “The best PFS results we’ve ever seen in relapsed, refractory myeloma.”
The combination of teclistamab (Tecvayli, Janssen) plus daratumumab (Darzalex, Johnson & Johnson/Janssen) reduced the risk for disease progression or death 83% from standard daratumumab and dexamethasone with either pomalidomide or bortezomib, according to findings of a randomized phase 3 trial presented at ASH Annual Meeting and Exposition and co-published in The New England Journal of Medicine.
Teclistamab plus daratumumab (Tec-Dara) also significantly improved response as patients who received the therapy